tirzepatide cardiovascular outcomes study In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT tirzepatide cardiovascular outcomes trial results
Pay in 4 interest-free payments of $7.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
















:max_bytes(150000):strip_icc()/VWH-GettyImages-2196287905-42e440cc5f714dfb8793161a905904d9.jpg)










